{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:20:10Z","timestamp":1783952410970,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Many antiseizure medications (ASMs) control seizures by blocking voltage-dependent sodium channels. Polymorphisms of sodium channel genes may affect the response to ASMs due to altering the effect of ASMs on blocking sodium channels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective study of epilepsy patients followed up at the Neurological Department of Kaohsiung Chang Gung Memorial Hospital, Taiwan between January 2010 and December 2018. We categorized the patients into response, partial response, and failure to sodium channel blocking ASM groups. Sodium channel blocking ASMs included phenytoin, carbamazepine, lamotrigine, oxcarbazepine, lacosamide, zonisamide, topiramate, and valproic acid. A subgroup of predominant sodium channel blocking ASMs included phenytoin, carbamazepine, lamotrigine, oxcarbazepine, and lacosamide. Associations between the response of ASMs and single-nucleotide polymorphisms of <jats:italic>SCN1A<\/jats:italic>, <jats:italic>SCN1B<\/jats:italic>, <jats:italic>SCN2A<\/jats:italic>, and <jats:italic>SCN9A<\/jats:italic> were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Two hundred Taiwanese patients and 21 single-nucleotide polymorphisms among <jats:italic>SCN1A<\/jats:italic>, <jats:italic>SCN1B<\/jats:italic>, <jats:italic>SCN2A<\/jats:italic>, and <jats:italic>SCN9A<\/jats:italic> were evaluated. We found allele C of rs55742440 in <jats:italic>SCN1B<\/jats:italic> was statistically significantly associated with not achieving seizure-free with sodium channel blocking ASMs. For the predominant sodium channel blocking ASMs group, no SNPs were associated with the response of ASMs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Single-nucleotide polymorphism in <jats:italic>SCN1B<\/jats:italic> was associated with the response to sodium channel blocking ASMs. This highlights the possibility that beta subunits may affect the function of sodium channels and resulted in different responsiveness to ASMs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-021-02395-2","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T04:03:41Z","timestamp":1632369821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Response to Sodium Channel blocking Antiseizure medications and coding polymorphisms of Sodium Channel genes in Taiwanese epilepsy patients"],"prefix":"10.1186","volume":"21","author":[{"given":"Chih-Hsiang","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Jui","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Ting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Han","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"issue":"3","key":"2395_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/epi.12074","volume":"54","author":"T Glauser","year":"2013","unstructured":"Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kalviainen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551\u201363. https:\/\/doi.org\/10.1111\/epi.12074.","journal-title":"Epilepsia"},{"issue":"5","key":"2395_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJM200002033420503","volume":"342","author":"P Kwan","year":"2000","unstructured":"Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314\u20139. https:\/\/doi.org\/10.1056\/NEJM200002033420503.","journal-title":"N Engl J Med"},{"issue":"6","key":"2395_CR3","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010;51(6):1069\u201377. https:\/\/doi.org\/10.1111\/j.1528-1167.2009.02397.x.","journal-title":"Epilepsia"},{"issue":"2","key":"2395_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.0013-9580.2005.31904.x","volume":"46","author":"P Kwan","year":"2005","unstructured":"Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005;46(2):224\u201335. https:\/\/doi.org\/10.1111\/j.0013-9580.2005.31904.x.","journal-title":"Epilepsia"},{"issue":"6","key":"2395_CR5","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.mehy.2011.02.039","volume":"76","author":"M Fang","year":"2011","unstructured":"Fang M, Xi ZQ, Wu Y, Wang XF. A new hypothesis of drug refractory epilepsy: neural network hypothesis. Med Hypotheses. 2011;76(6):871\u20136. https:\/\/doi.org\/10.1016\/j.mehy.2011.02.039.","journal-title":"Med Hypotheses"},{"issue":"5","key":"2395_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1535-7511.2008.00272.x","volume":"8","author":"MA Rogawski","year":"2008","unstructured":"Rogawski MA, Johnson MR. Intrinsic severity as a determinant of antiepileptic drug refractoriness. Epilepsy Curr. 2008;8(5):127\u201330. https:\/\/doi.org\/10.1111\/j.1535-7511.2008.00272.x.","journal-title":"Epilepsy Curr"},{"issue":"4","key":"2395_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/ana.10473","volume":"53","author":"S Remy","year":"2003","unstructured":"Remy S, Gabriel S, Urban BW, Dietrich D, Lehmann TN, Elger CE, et al. A novel mechanism underlying drug resistance in chronic epilepsy. Ann Neurol. 2003;53(4):469\u201379. https:\/\/doi.org\/10.1002\/ana.10473.","journal-title":"Ann Neurol"},{"issue":"2","key":"2395_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejpn.2005.11.009","volume":"10","author":"C Depondt","year":"2006","unstructured":"Depondt C. The potential of pharmacogenetics in the treatment of epilepsy. Eur J Paediatr Neurol. 2006;10(2):57\u201365. https:\/\/doi.org\/10.1016\/j.ejpn.2005.11.009.","journal-title":"Eur J Paediatr Neurol"},{"issue":"1 Epilepsy","key":"2395_CR9","first-page":"132","volume":"22","author":"BW Abou-Khalil","year":"2016","unstructured":"Abou-Khalil BW. Antiepileptic Drugs. Continuum (Minneap Minn). 2016;22(1 Epilepsy):132\u201356.","journal-title":"Continuum (Minneap Minn)"},{"issue":"8","key":"2395_CR10","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1172\/JCI25466","volume":"115","author":"MH Meisler","year":"2005","unstructured":"Meisler MH, Kearney JA. Sodium channel mutations in epilepsy and other neurological disorders. J Clin Invest. 2005;115(8):2010\u20137. https:\/\/doi.org\/10.1172\/JCI25466.","journal-title":"J Clin Invest"},{"issue":"15","key":"2395_CR11","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1073\/pnas.0407346102","volume":"102","author":"SK Tate","year":"2005","unstructured":"Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A. 2005;102(15):5507\u201312. https:\/\/doi.org\/10.1073\/pnas.0407346102.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2395_CR12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/j.1365-2125.2008.03203.x","volume":"66","author":"T Abe","year":"2008","unstructured":"Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br J Clin Pharmacol. 2008;66(2):304\u20137. https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03203.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2395_CR13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.5114\/aoms.2016.59737","volume":"13","author":"C Angelopoulou","year":"2017","unstructured":"Angelopoulou C, Veletza S, Heliopoulos I, Vadikolias K, Tripsianis G, Stathi C, et al. Association of SCN1A gene polymorphism with antiepileptic drug responsiveness in the population of Thrace. Greece Arch Med Sci. 2017;13(1):138\u201347. https:\/\/doi.org\/10.5114\/aoms.2016.59737.","journal-title":"Greece Arch Med Sci"},{"issue":"10","key":"2395_CR14","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2217\/pgs.14.89","volume":"15","author":"CL Ma","year":"2014","unstructured":"Ma CL, Wu XY, Zheng J, Wu ZY, Hong Z, Zhong MK. Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy. Pharmacogenomics. 2014;15(10):1323\u201336. https:\/\/doi.org\/10.2217\/pgs.14.89.","journal-title":"Pharmacogenomics"},{"issue":"5","key":"2395_CR15","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1111\/j.1528-1167.2011.03097.x","volume":"52","author":"I Manna","year":"2011","unstructured":"Manna I, Gambardella A, Bianchi A, Striano P, Tozzi R, Aguglia U, et al. A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia. 2011;52(5):e40\u20134. https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03097.x.","journal-title":"Epilepsia"},{"issue":"6","key":"2395_CR16","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.biochi.2013.02.006","volume":"95","author":"R Kumari","year":"2013","unstructured":"Kumari R, Lakhan R, Kumar S, Garg RK, Misra UK, Kalita J, et al. SCN1AIVS5-91G-->a polymorphism is associated with susceptibility to epilepsy but not with drug responsiveness. Biochimie. 2013;95(6):1350\u20133. https:\/\/doi.org\/10.1016\/j.biochi.2013.02.006.","journal-title":"Biochimie"},{"issue":"2","key":"2395_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.seizure.2009.12.004","volume":"19","author":"MB Sanchez","year":"2010","unstructured":"Sanchez MB, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizan EM, et al. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure. 2010;19(2):93\u2013101. https:\/\/doi.org\/10.1016\/j.seizure.2009.12.004.","journal-title":"Seizure"},{"issue":"4","key":"2395_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/tpj.2013.43","volume":"14","author":"TS Yip","year":"2014","unstructured":"Yip TS, O'Doherty C, Tan NC, Dibbens LM, Suppiah V. SCN1A variations and response to multiple antiepileptic drugs. Pharmacogenomics J. 2014;14(4):385\u20139. https:\/\/doi.org\/10.1038\/tpj.2013.43.","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"2395_CR19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1365-2125.2009.03437.x","volume":"68","author":"R Lakhan","year":"2009","unstructured":"Lakhan R, Kumari R, Misra UK, Kalita J, Pradhan S, Mittal B. Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. Br J Clin Pharmacol. 2009;68(2):214\u201320. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03437.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"2395_CR20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1097\/FPC.0b013e3283117d67","volume":"18","author":"P Kwan","year":"2008","unstructured":"Kwan P, Poon WS, Ng HK, Kang DE, Wong V, Ng PW, et al. Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomics. 2008;18(11):989\u201398. https:\/\/doi.org\/10.1097\/FPC.0b013e3283117d67.","journal-title":"Pharmacogenet Genomics"},{"issue":"10","key":"2395_CR21","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2217\/pgs.13.104","volume":"14","author":"BS Haerian","year":"2013","unstructured":"Haerian BS, Baum L, Kwan P, Tan HJ, Raymond AA, Mohamed Z. SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis. Pharmacogenomics. 2013;14(10):1153\u201366. https:\/\/doi.org\/10.2217\/pgs.13.104.","journal-title":"Pharmacogenomics"},{"issue":"7","key":"2395_CR22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40263-017-0441-0","volume":"31","author":"MJ Brodie","year":"2017","unstructured":"Brodie MJ. Sodium Channel blockers in the treatment of epilepsy. CNS Drugs. 2017;31(7):527\u201334. https:\/\/doi.org\/10.1007\/s40263-017-0441-0.","journal-title":"CNS Drugs"},{"issue":"3","key":"2395_CR23","doi-asserted-by":"publisher","first-page":"146","DOI":"10.4161\/chan.24380","volume":"7","author":"M Abdelsayed","year":"2013","unstructured":"Abdelsayed M, Sokolov S. Voltage-gated sodium channels: pharmaceutical targets via anticonvulsants to treat epileptic syndromes. Channels (Austin). 2013;7(3):146\u201352. https:\/\/doi.org\/10.4161\/chan.24380.","journal-title":"Channels (Austin)"},{"issue":"10","key":"2395_CR24","doi-asserted-by":"publisher","first-page":"E904","DOI":"10.1002\/humu.21083","volume":"30","author":"LR Claes","year":"2009","unstructured":"Claes LR, Deprez L, Suls A, Baets J, Smets K, Van Dyck T, et al. The SCN1A variant database: a novel research and diagnostic tool. Hum Mutat. 2009;30(10):E904\u201320. https:\/\/doi.org\/10.1002\/humu.21083.","journal-title":"Hum Mutat"},{"issue":"4","key":"2395_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/epi.16467","volume":"61","author":"S Wolking","year":"2020","unstructured":"Wolking S, Moreau C, Nies AT, Schaeffeler E, McCormack M, Auce P, et al. Testing association of rare genetic variants with resistance to three common antiseizure medications. Epilepsia. 2020;61(4):657\u201366.","journal-title":"Epilepsia"},{"issue":"4","key":"2395_CR26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","volume":"58","author":"IE Scheffer","year":"2017","unstructured":"Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512\u201321. https:\/\/doi.org\/10.1111\/epi.13709.","journal-title":"Epilepsia"},{"issue":"4","key":"2395_CR27","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/epi.13670","volume":"58","author":"RS Fisher","year":"2017","unstructured":"Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):522\u201330. https:\/\/doi.org\/10.1111\/epi.13670.","journal-title":"Epilepsia"},{"issue":"3","key":"2395_CR28","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1006\/geno.1994.1551","volume":"23","author":"N Makita","year":"1994","unstructured":"Makita N, Sloan-Brown K, Weghuis DO, Ropers HH, George AL Jr. Genomic organization and chromosomal assignment of the human voltage-gated Na+ channel beta 1 subunit gene (SCN1B). Genomics. 1994;23(3):628\u201334. https:\/\/doi.org\/10.1006\/geno.1994.1551.","journal-title":"Genomics"},{"issue":"1","key":"2395_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0896-6273(00)81133-2","volume":"26","author":"WA Catterall","year":"2000","unstructured":"Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron. 2000;26(1):13\u201325. https:\/\/doi.org\/10.1016\/S0896-6273(00)81133-2.","journal-title":"Neuron"},{"issue":"1","key":"2395_CR30","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1146\/annurev-physiol-021014-071846","volume":"77","author":"HA O'Malley","year":"2015","unstructured":"O'Malley HA, Isom LL. Sodium channel beta subunits: emerging targets in channelopathies. Annu Rev Physiol. 2015;77(1):481\u2013504. https:\/\/doi.org\/10.1146\/annurev-physiol-021014-071846.","journal-title":"Annu Rev Physiol"},{"issue":"11","key":"2395_CR31","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1111\/epi.13889","volume":"58","author":"D Steel","year":"2017","unstructured":"Steel D, Symonds JD, Zuberi SM, Brunklaus A. Dravet syndrome and its mimics: beyond SCN1A. Epilepsia. 2017;58(11):1807\u201316. https:\/\/doi.org\/10.1111\/epi.13889.","journal-title":"Epilepsia"},{"key":"2395_CR32","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fphar.2015.00108","volume":"6","author":"D Baroni","year":"2015","unstructured":"Baroni D, Moran O. On the multiple roles of the voltage gated sodium channel beta1 subunit in genetic diseases. Front Pharmacol. 2015;6:108. https:\/\/doi.org\/10.3389\/fphar.2015.00108.","journal-title":"Front Pharmacol"},{"issue":"11","key":"2395_CR33","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1111\/j.1528-1167.2012.03675.x","volume":"53","author":"M Uebachs","year":"2012","unstructured":"Uebachs M, Albus C, Opitz T, Isom L, Niespodziany I, Wolff C, et al. Loss of beta1 accessory Na+ channel subunits causes failure of carbamazepine, but not of lacosamide, in blocking high-frequency firing via differential effects on persistent Na+ currents. Epilepsia. 2012;53(11):1959\u201367. https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03675.x.","journal-title":"Epilepsia"},{"issue":"25","key":"2395_CR34","doi-asserted-by":"publisher","first-page":"8489","DOI":"10.1523\/JNEUROSCI.1534-10.2010","volume":"30","author":"M Uebachs","year":"2010","unstructured":"Uebachs M, Opitz T, Royeck M, Dickhof G, Horstmann MT, Isom LL, et al. Efficacy loss of the anticonvulsant carbamazepine in mice lacking sodium channel beta subunits via paradoxical effects on persistent sodium currents. J Neurosci. 2010;30(25):8489\u2013501. https:\/\/doi.org\/10.1523\/JNEUROSCI.1534-10.2010.","journal-title":"J Neurosci"},{"issue":"3","key":"2395_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.eplepsyres.2005.03.003","volume":"64","author":"PT Lucas","year":"2005","unstructured":"Lucas PT, Meadows LS, Nicholls J, Ragsdale DS. An epilepsy mutation in the beta1 subunit of the voltage-gated sodium channel results in reduced channel sensitivity to phenytoin. Epilepsy Res. 2005;64(3):77\u201384. https:\/\/doi.org\/10.1016\/j.eplepsyres.2005.03.003.","journal-title":"Epilepsy Res"},{"issue":"7616","key":"2395_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285\u201391. https:\/\/doi.org\/10.1038\/nature19057.","journal-title":"Nature"},{"key":"2395_CR37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.atg.2012.06.001","volume":"1","author":"L Refsgaard","year":"2012","unstructured":"Refsgaard L, Olesen MS, Moller DV, Christiansen M, Haunso S, Svendsen JH, et al. Mutation analysis of the candidate genes SCN1B-4B, FHL1, and LMNA in patients with arrhythmogenic right ventricular cardiomyopathy. Appl Transl Genom. 2012;1:44\u20136. https:\/\/doi.org\/10.1016\/j.atg.2012.06.001.","journal-title":"Appl Transl Genom"},{"issue":"1","key":"2395_CR38","doi-asserted-by":"publisher","first-page":"6470","DOI":"10.1038\/srep06470","volume":"4","author":"MT Ricci","year":"2014","unstructured":"Ricci MT, Menegon S, Vatrano S, Mandrile G, Cerrato N, Carvalho P, et al. SCN1B gene variants in Brugada syndrome: a study of 145 SCN5A-negative patients. Sci Rep. 2014;4(1):6470. https:\/\/doi.org\/10.1038\/srep06470.","journal-title":"Sci Rep"},{"key":"2395_CR39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3389\/fcell.2019.00261","volume":"7","author":"I El-Battrawy","year":"2019","unstructured":"El-Battrawy I, Muller J, Zhao Z, Cyganek L, Zhong R, Zhang F, et al. Studying Brugada syndrome with an SCN1B variants in human-induced pluripotent stem cell-derived cardiomyocytes. Front Cell Dev Biol. 2019;7:261. https:\/\/doi.org\/10.3389\/fcell.2019.00261.","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"2395_CR40","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/archneurol.2009.211","volume":"66","author":"Y Schiller","year":"2009","unstructured":"Schiller Y. Seizure relapse and development of drug resistance following long-term seizure remission. Arch Neurol. 2009;66(10):1233\u20139. https:\/\/doi.org\/10.1001\/archneurol.2009.211.","journal-title":"Arch Neurol"},{"issue":"3","key":"2395_CR41","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1528-1167.2010.02929.x","volume":"52","author":"B Callaghan","year":"2011","unstructured":"Callaghan B, Schlesinger M, Rodemer W, Pollard J, Hesdorffer D, Allen Hauser W, et al. Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia. 2011;52(3):619\u201326. https:\/\/doi.org\/10.1111\/j.1528-1167.2010.02929.x.","journal-title":"Epilepsia"},{"issue":"11","key":"2395_CR42","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1111\/epi.14565","volume":"59","author":"X Chi","year":"2018","unstructured":"Chi X, Li R, Hao X, Chen J, Xiong W, Xu H, et al. Response to treatment schedules after the first antiepileptic drug failed. Epilepsia. 2018;59(11):2118\u201324. https:\/\/doi.org\/10.1111\/epi.14565.","journal-title":"Epilepsia"},{"issue":"5","key":"2395_CR43","doi-asserted-by":"publisher","first-page":"e1000477","DOI":"10.1371\/journal.pgen.1000477","volume":"5","author":"CC Spencer","year":"2009","unstructured":"Spencer CC, Su Z, Donnelly P, Marchini J. Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip. PLoS Genet. 2009;5(5):e1000477. https:\/\/doi.org\/10.1371\/journal.pgen.1000477.","journal-title":"PLoS Genet"},{"issue":"2","key":"2395_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/00125817-200203000-00002","volume":"4","author":"JN Hirschhorn","year":"2002","unstructured":"Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med. 2002;4(2):45\u201361. https:\/\/doi.org\/10.1097\/00125817-200203000-00002.","journal-title":"Genet Med"},{"issue":"7","key":"2395_CR45","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/epi.16091","volume":"60","author":"A Pitkanen","year":"2019","unstructured":"Pitkanen A, Henshall DC, Cross JH, Guerrini R, Jozwiak S, Kokaia M, et al. Advancing research toward faster diagnosis, better treatment, and end of stigma in epilepsy. Epilepsia. 2019;60(7):1281\u201392. https:\/\/doi.org\/10.1111\/epi.16091.","journal-title":"Epilepsia"},{"issue":"10","key":"2395_CR46","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nrg1916","volume":"7","author":"DJ Balding","year":"2006","unstructured":"Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet. 2006;7(10):781\u201391. https:\/\/doi.org\/10.1038\/nrg1916.","journal-title":"Nat Rev Genet"},{"issue":"3","key":"2395_CR47","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/ejhg.2013.144","volume":"22","author":"AE Hendricks","year":"2014","unstructured":"Hendricks AE, Dupuis J, Logue MW, Myers RH, Lunetta KL. Correction for multiple testing in a gene region. Eur J Hum Genet. 2014;22(3):414\u20138. https:\/\/doi.org\/10.1038\/ejhg.2013.144.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"2395_CR48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ajhg.2017.06.005","volume":"101","author":"PM Visscher","year":"2017","unstructured":"Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, et al. 10 years of GWAS discovery: biology, function, and translation. Am J Hum Genet. 2017;101(1):5\u201322. https:\/\/doi.org\/10.1016\/j.ajhg.2017.06.005.","journal-title":"Am J Hum Genet"},{"issue":"Pt B","key":"2395_CR49","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.brainres.2015.07.005","volume":"1628","author":"H Qosa","year":"2015","unstructured":"Qosa H, Miller DS, Pasinelli P, Trotti D. Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders. Brain Res. 2015;1628(Pt B):298\u2013316.","journal-title":"Brain Res"},{"issue":"1","key":"2395_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.yebeh.2011.02.015","volume":"21","author":"H Meng","year":"2011","unstructured":"Meng H, Guo G, Ren J, Zhou H, Ge Y, Guo Y. Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Behav. 2011;21(1):27\u201330. https:\/\/doi.org\/10.1016\/j.yebeh.2011.02.015.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"2395_CR51","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2217\/14622416.7.4.551","volume":"7","author":"T Seo","year":"2006","unstructured":"Seo T, Ishitsu T, Ueda N, Nakada N, Yurube K, Ueda K, et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics. 2006;7(4):551\u201361. https:\/\/doi.org\/10.2217\/14622416.7.4.551.","journal-title":"Pharmacogenomics"},{"issue":"1\u20132","key":"2395_CR52","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000109264","volume":"59","author":"GO Ozgon","year":"2008","unstructured":"Ozgon GO, Bebek N, Gul G, Cine N. Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey. Eur Neurol. 2008;59(1\u20132):67\u201370. https:\/\/doi.org\/10.1159\/000109264.","journal-title":"Eur Neurol"},{"issue":"1","key":"2395_CR53","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1517\/phgs.5.1.67.25683","volume":"5","author":"T Ishikawa","year":"2004","unstructured":"Ishikawa T, Tsuji A, Inui K, Sai Y, Anzai N, Wada M, et al. The genetic polymorphism of drug transporters: functional analysis approaches. Pharmacogenomics. 2004;5(1):67\u201399. https:\/\/doi.org\/10.1517\/phgs.5.1.67.25683.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"2395_CR54","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1146\/annurev.pharmtox.37.1.269","volume":"37","author":"UA Meyer","year":"1997","unstructured":"Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol. 1997;37(1):269\u201396. https:\/\/doi.org\/10.1146\/annurev.pharmtox.37.1.269.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"2395_CR55","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2217\/pgs.11.141","volume":"13","author":"CC Hung","year":"2012","unstructured":"Hung CC, Chang WL, Ho JL, Tai JJ, Hsieh TJ, Huang HC, et al. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics. 2012;13(2):159\u201369. https:\/\/doi.org\/10.2217\/pgs.11.141.","journal-title":"Pharmacogenomics"},{"issue":"4","key":"2395_CR56","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2217\/pgs.14.186","volume":"16","author":"CL Ma","year":"2015","unstructured":"Ma CL, Wu XY, Jiao Z, Hong Z, Wu ZY, Zhong MK. SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy. Pharmacogenomics. 2015;16(4):347\u201360. https:\/\/doi.org\/10.2217\/pgs.14.186.","journal-title":"Pharmacogenomics"},{"key":"2395_CR57","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.neulet.2017.05.014","volume":"667","author":"A Orsini","year":"2018","unstructured":"Orsini A, Zara F, Striano P. Recent advances in epilepsy genetics. Neurosci Lett. 2018;667:4\u20139. https:\/\/doi.org\/10.1016\/j.neulet.2017.05.014.","journal-title":"Neurosci Lett"},{"issue":"1","key":"2395_CR58","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13073-015-0214-7","volume":"7","author":"CT Myers","year":"2015","unstructured":"Myers CT, Mefford HC. Advancing epilepsy genetics in the genomic era. Genome Med. 2015;7(1):91. https:\/\/doi.org\/10.1186\/s13073-015-0214-7.","journal-title":"Genome Med"},{"issue":"13","key":"2395_CR59","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.2217\/pgs.12.127","volume":"13","author":"BS Haerian","year":"2012","unstructured":"Haerian BS, Baum L, Tan HJ, Kwan P, Raymond AA, Saruwatari J, et al. SCN1A IVS5N+5 polymorphism and response to sodium valproate: a multicenter study. Pharmacogenomics. 2012;13(13):1477\u201385. https:\/\/doi.org\/10.2217\/pgs.12.127.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"2395_CR60","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3346\/jkms.2009.24.1.62","volume":"24","author":"SY Jang","year":"2009","unstructured":"Jang SY, Kim MK, Lee KR, Park MS, Kim BC, Cho KH, et al. Gene-to-gene interaction between sodium channel-related genes in determining the risk of antiepileptic drug resistance. J Korean Med Sci. 2009;24(1):62\u20138. https:\/\/doi.org\/10.3346\/jkms.2009.24.1.62.","journal-title":"J Korean Med Sci"},{"issue":"9","key":"2395_CR61","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41576-018-0018-x","volume":"19","author":"A Torkamani","year":"2018","unstructured":"Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet. 2018;19(9):581\u201390. https:\/\/doi.org\/10.1038\/s41576-018-0018-x.","journal-title":"Nat Rev Genet"},{"issue":"9984","key":"2395_CR62","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1016\/S0140-6736(14)61730-X","volume":"385","author":"JL Mega","year":"2015","unstructured":"Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield M, Devlin JJ, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015;385(9984):2264\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(14)61730-X.","journal-title":"Lancet"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02395-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-021-02395-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02395-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T04:03:57Z","timestamp":1632369837000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-021-02395-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2395"],"URL":"https:\/\/doi.org\/10.1186\/s12883-021-02395-2","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,23]]},"assertion":[{"value":"27 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Chang Gung Medical Foundation Institutional Review Board (IRB No.: 104-1961C, 104-2308B, 201800433B0D001, and 201901274B0D001). This study was carried out according to the Declaration of Helsinki. Prior to enrollment, all patients or their legal proxies will be given detailed information about the aims, scope, and possible consequences of the trial by a physician. Written informed consent was obtained from all study participants or their legal proxies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"367"}}